ABSTRACT
The aim of this study was to develop a realistic network model to predict qualitatively the relationship between lockdown duration and coverage in controlling the progression of the incidence curve of an epidemic with the characteristics of COVID-19 in a closed and non-immune population.
Effects of lockdown time and rate on the progression of an epidemic incidence curve in a virtual closed population of 10 thousand subjects. Predictor variables were R0 values established in the most recent literature (2.7 and 5.7), without lockdown and with coverages of 25%, 50%, and 90% for 21, 35, 70, and 140 days in 13 different scenarios for each R0, where individuals remained infected and transmitters for 14 days. We estimated model validity by applying an exponential model on the incidence curve with no lockdown, with growth rate coefficient observed in realistic scenarios. Pairwise comparisons were performed using Wilcoxon test with Bonferroni correction between peak amplitude, peak latency, and total number of cases for each R0 used.
For R0=5.7, the flattening of the curve occurs only with long lockdown periods (70 and 140 days) with a 90% coverage. For R0=2.7, coverages of 25 and 50% also result in curve flattening and reduction of total cases, provided they occur for a long period (70 days or more). Short and soft lockdowns had no relevant effect on incidence or casuistry.
These data corroborate the importance of lockdown duration regardless of virus transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has no funding support
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes